Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
The treatment of colorectal cancer (CRC) has remained a significant clinical challenge, since over 50% of patients present with or develop liver metastases, which is a leading cause of death; however, a recent phase III study showed promise for selective internal radiation therapy (SIRT) in combination with standard chemotherapy as a first-line treatment.
Preliminary data shows an anthracycline/taxane-based chemotherapy regimen (TaxAC) could be superior to docetaxal plus cyclophosphamide in patients with breast cancer.
Screening for microsatellite instability in patients with colorectal cancer tumors is a significant step in determining which patients will benefit from immunotherapy, specifically pembrolizumab.
Precision oncology should play a vital role in the shift toward value-based medicine by helping to deliver more effective therapies with more manageable pricing profiles, according to John L. Marshall, MD.
Multigene panel testing may uncover new risks in breast cancer and ovarian cancer.